Question. Has anyone on this board sold ESA's, as I have?
The 37 percent reduction is not that impressive...13k down to 10k IU's. For instance the unites given of EPO for the average oncology patients is 40K IU's. The dialysis market is different I know, but that little reduction is not going to impress the Nephs much, they are still going to have to treat with growth factors. Also, the p-value of 0.034 in that small study is also not too impressive, as a larger study usually dilutes the p-values of small studies. Just playing devils advocate. Anyone with intelligent input please respond. Cost analysis would be good to see.
You are another short bashing the company! Get a life you loser!
A 37% reduction is more than impressive. The FDA is impressed and has SFP on the fast track.
It beats the heck out of toxic Iron Injections that make the patient feel like #$%$". I personally know of a patient that was on SFP during one of the Cruise studies and wanted to stay on it because he felt so much better. He had more energy and was able to do normal things he had not done for a long time.
This is about the patient (s) and how it benefits them, not about a.. h.... like you that just post negatives with the hope of driving driving the price down!!
You are plain and simply losers and your day is coming when we will never have to hear from you again!
It is one thing to post informative and factual information but to just continually bash and say stupid things with no scientific facts is a testament to your character.